[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Wall St Engine [@wallstengine](/creator/twitter/wallstengine) on x 72.7K followers Created: 2025-06-03 12:24:23 UTC $AGEN SELLS U.S. BIOLOGICS FACILITIES TO ZYDUS FOR UP TO $125M Agenus is selling its biologics manufacturing sites in Emeryville and Berkeley, CA to Zydus Lifesciences for $75M upfront, plus up to $50M in milestone payments. Zydus gains a U.S. base for its new CDMO business and will exclusively manufacture Agenus’ Phase 3-ready cancer drugs Botensilimab and Balstilimab. The deal gives Zydus a foothold in the growing global biologics market. XXXXX engagements  **Related Topics** [50m](/topic/50m) [drugs](/topic/drugs) [$50m](/topic/$50m) [$75m](/topic/$75m) [$zyduslifebo](/topic/$zyduslifebo) [$125m](/topic/$125m) [$agen](/topic/$agen) [Post Link](https://x.com/wallstengine/status/1929876818812981645)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Wall St Engine @wallstengine on x 72.7K followers
Created: 2025-06-03 12:24:23 UTC
$AGEN SELLS U.S. BIOLOGICS FACILITIES TO ZYDUS FOR UP TO $125M
Agenus is selling its biologics manufacturing sites in Emeryville and Berkeley, CA to Zydus Lifesciences for $75M upfront, plus up to $50M in milestone payments. Zydus gains a U.S. base for its new CDMO business and will exclusively manufacture Agenus’ Phase 3-ready cancer drugs Botensilimab and Balstilimab. The deal gives Zydus a foothold in the growing global biologics market.
XXXXX engagements
